China A-share innovative drug stocks retreat; Baicheng Pharma plunges over 15%

A double-digit single-stock drop alongside a brief limit-down in a peer points to a sector-wide de-rating rather than an isolated miss, and the absence of a named catalyst makes the move itself the story. What matters is breadth: the declines span CDMO exposure like Asymchem and commercial-stage names like Allist, suggesting sentiment toward the whole innovative-drug complex is being repriced rather than one pipeline readout. The open question is whether this proves a one-session shakeout or the start of a sustained rotation out of the sector, and whether follow-through selling appears in the smaller names that moved hardest.